Suppr超能文献

去甲肾上腺素治疗危重症患者的身体活动:一项回顾性队列研究。

Mobilisation of critically ill patients receiving norepinephrine: a retrospective cohort study.

机构信息

Department of Anesthesiology and Operative Intensive Care Medicine (CVK, CCM), Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität Zu Berlin, Berlin, Germany.

Department of Anesthesiology and Intensive Care, School of Medicine, Technical University of Munich, Munich, Germany.

出版信息

Crit Care. 2022 Nov 25;26(1):362. doi: 10.1186/s13054-022-04245-0.

Abstract

BACKGROUND

Mobilisation and exercise intervention in general are safe and feasible in critically ill patients. For patients requiring catecholamines, however, doses of norepinephrine safe for mobilisation in the intensive care unit (ICU) are not defined. This study aimed to describe mobilisation practice in our hospital and identify doses of norepinephrine that allowed a safe mobilisation.

METHODS

We conducted a retrospective single-centre cohort study of 16 ICUs at a university hospital in Germany with patients admitted between March 2018 and November 2021. Data were collected from our patient data management system. We analysed the effect of norepinephrine on level (ICU Mobility Scale) and frequency (units per day) of mobilisation, early mobilisation (within 72 h of ICU admission), mortality, and rate of adverse events. Data were extracted from free-text mobilisation entries using supervised machine learning (support vector machine). Statistical analyses were done using (generalised) linear (mixed-effect) models, as well as chi-square tests and ANOVAs.

RESULTS

A total of 12,462 patients were analysed in this study. They received a total of 59,415 mobilisation units. Of these patients, 842 (6.8%) received mobilisation under continuous norepinephrine administration. Norepinephrine administration was negatively associated with the frequency of mobilisation (adjusted difference -0.07 mobilisations per day; 95% CI - 0.09, - 0.05; p ≤ 0.001) and early mobilisation (adjusted OR 0.83; 95% CI 0.76, 0.90; p ≤ 0.001), while a higher norepinephrine dose corresponded to a lower chance to be mobilised out-of-bed (adjusted OR 0.01; 95% CI 0.00, 0.04; p ≤ 0.001). Mobilisation with norepinephrine did not significantly affect mortality (p > 0.1). Higher compared to lower doses of norepinephrine did not lead to a significant increase in adverse events in our practice (p > 0.1). We identified that mobilisation was safe with up to 0.20 µg/kg/min norepinephrine for out-of-bed (IMS ≥ 2) and 0.33 µg/kg/min for in-bed (IMS 0-1) mobilisation.

CONCLUSIONS

Mobilisation with norepinephrine can be done safely when considering the status of the patient and safety guidelines. We demonstrated that safe mobilisation was possible with norepinephrine doses up to 0.20 µg/kg/min for out-of-bed (IMS ≥ 2) and 0.33 µg/kg/min for in-bed (IMS 0-1) mobilisation.

摘要

背景

在危重症患者中,动员和运动干预通常是安全且可行的。然而,对于需要儿茶酚胺的患者,尚无定义在重症监护病房(ICU)中进行动员的安全去甲肾上腺素剂量。本研究旨在描述我院的动员实践,并确定允许安全动员的去甲肾上腺素剂量。

方法

我们对德国一所大学医院的 16 个 ICU 进行了回顾性单中心队列研究,患者于 2018 年 3 月至 2021 年 11 月期间入院。数据来自我们的患者数据管理系统。我们分析了去甲肾上腺素对动员水平(重症监护病房活动量表)和频率(单位/天)、早期动员(ICU 入院后 72 小时内)、死亡率和不良事件发生率的影响。使用有监督的机器学习(支持向量机)从自由文本动员条目中提取数据。使用(广义)线性(混合效应)模型以及卡方检验和 ANOVA 进行统计分析。

结果

本研究共分析了 12462 名患者。他们总共接受了 59415 次动员单位。在这些患者中,842 名(6.8%)在持续给予去甲肾上腺素的情况下接受了动员。去甲肾上腺素的使用与动员频率呈负相关(调整后的差异-0.07 次/天;95%CI-0.09,-0.05;p≤0.001)和早期动员(调整后的 OR 0.83;95%CI 0.76,0.90;p≤0.001),而较高的去甲肾上腺素剂量与较低的离床动员机会相对应(调整后的 OR 0.01;95%CI 0.00,0.04;p≤0.001)。动员时使用去甲肾上腺素不会显著影响死亡率(p>0.1)。与较低剂量相比,较高剂量的去甲肾上腺素在我们的实践中并没有导致不良事件显著增加(p>0.1)。我们发现,当考虑到患者的状况和安全指南时,使用去甲肾上腺素进行动员是安全的。我们证明,在 0.20μg/kg/min 的去甲肾上腺素(IMS≥2)用于离床(IMS≥2)和 0.33μg/kg/min 的去甲肾上腺素(IMS 0-1)用于卧床动员时,可以安全进行动员。

结论

在考虑患者状况和安全指南的情况下,使用去甲肾上腺素进行动员是安全的。我们表明,在 0.20μg/kg/min 的去甲肾上腺素(IMS≥2)用于离床(IMS≥2)和 0.33μg/kg/min 的去甲肾上腺素(IMS 0-1)用于卧床动员时,可以安全地进行动员。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56b2/9700948/ae3f66d63c46/13054_2022_4245_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验